Hansoh Pharma proposes director re-election, share mandates, and dividend

Hansoh Pharmaceutical Group (HKEX: 3692) has released details of resolutions to be proposed at its Annual General Meeting on June 20, 2025. Shareholders will vote on the re-election of executive director Sun Yuan and independent non-executive director Chan Charles Sheung Wai. The board is also seeking a general mandate to repurchase up to 10% of the company's issued shares and to issue new shares up to 20% of the current total. The company proposes a final dividend of HKD0.1353 per share, payable on July 25, 2025, to shareholders on record as of July 9, 2025. Ernst & Young are proposed for re-appointment as auditors.